B-intervention	0	13	Gonadatrophin
I-intervention	14	25	suppression
O	26	28	to
O	29	36	prevent
B-condition	37	49	chemotherapy
I-condition	49	50	-
I-condition	50	57	induced
I-condition	58	65	ovarian
I-condition	66	72	damage
O	72	73	:
O	74	75	a
O	76	86	randomized
O	87	97	controlled
O	98	103	trial
O	103	104	.

O	105	107	To
O	108	116	estimate
O	117	120	the
O	121	134	effectiveness
O	135	137	of
O	138	150	gonadotropin
O	150	151	-
O	151	160	releasing
O	161	168	hormone
O	169	170	(
O	170	174	GnRH
O	174	175	)
O	176	185	analogues
O	186	197	cotreatment
O	198	200	in
O	201	211	preventing
O	212	224	chemotherapy
O	224	225	-
O	225	232	induced
O	233	243	amenorrhea
O	244	246	in
O	247	252	young
O	253	259	breast
O	260	266	cancer
O	267	275	patients
O	276	286	undergoing
O	287	303	cyclophosphamide
O	303	304	-
O	304	309	based
O	310	322	chemotherapy
O	322	323	.

B-total-participants	324	327	One
I-total-participants	328	335	hundred
B-eligibility	336	343	hormone
I-eligibility	343	344	-
I-eligibility	344	355	insensitive
I-eligibility	356	362	breast
I-eligibility	363	369	cancer
I-eligibility	370	382	participants
O	383	384	(
O	384	388	aged
B-age	389	391	18
I-age	391	392	-
I-age	392	394	40
I-age	395	400	years
O	400	401	)
O	402	406	were
O	407	416	recruited
O	417	421	from
O	422	425	two
O	426	436	university
O	436	437	-
O	437	447	affiliated
O	448	456	oncology
O	457	464	centers
O	465	467	in
B-location	468	473	Egypt
O	473	474	.

O	475	481	Opting
O	482	485	for
O	486	490	type
O	491	493	of
O	494	505	cotreatment
O	506	509	was
O	510	515	based
O	516	518	on
O	519	528	available
O	529	538	timeframe
O	539	544	until
O	545	550	start
O	551	553	of
O	554	566	chemotherapy
O	566	567	.

B-total-participants	568	573	Fifty
O	574	579	women
O	580	585	ready
O	586	589	for
O	590	595	early
O	596	608	chemotherapy
O	609	613	were
O	614	624	randomized
O	625	627	to
O	628	635	receive
O	636	642	either
B-control	643	655	chemotherapy
I-control	656	661	alone
O	662	663	(
O	663	666	arm
O	667	668	I
O	668	669	)
O	670	672	or
O	673	685	chemotherapy
O	686	691	after
O	692	706	downregulation
O	707	708	(
O	708	717	estradiol
O	718	722	less
O	723	727	than
O	728	730	50
O	731	733	pg
O	733	734	/
O	734	736	mL
O	736	737	)
O	738	740	by
O	741	745	GnRH
O	746	756	antagonist
O	757	760	and
O	761	768	agonist
O	769	770	(
O	770	773	arm
O	774	776	II
O	776	777	)
O	777	778	.

O	779	783	Then
O	783	784	,
O	785	789	GnRH
O	790	800	antagonist
O	801	804	was
O	805	817	discontinued
O	818	821	and
O	822	829	agonist
O	830	833	was
O	834	843	continued
O	844	849	until
O	850	853	the
O	854	857	end
O	858	860	of
O	861	873	chemotherapy
O	873	874	.

O	875	879	When
O	880	892	chemotherapy
O	893	896	was
O	897	899	to
O	900	905	start
O	906	911	later
O	912	916	than
O	917	919	10
O	920	924	days
O	925	930	after
O	931	936	study
O	937	946	inclusion
O	946	947	,
B-total-participants	948	950	50
O	951	956	women
O	957	961	were
O	962	972	randomized
O	973	975	to
O	976	983	receive
O	984	990	either
O	991	1003	chemotherapy
O	1004	1009	alone
O	1010	1011	(
O	1011	1014	arm
O	1015	1018	III
O	1018	1019	)
O	1020	1022	or
O	1023	1035	chemotherapy
O	1036	1041	after
O	1042	1056	downregulation
O	1057	1061	with
O	1062	1066	GnRH
O	1067	1074	agonist
O	1075	1076	(
O	1076	1079	arm
O	1080	1082	IV
O	1082	1083	)
O	1083	1084	.

B-outcome-Measure	1085	1095	Resumption
I-outcome-Measure	1096	1098	of
I-outcome-Measure	1099	1111	menstruation
I-outcome-Measure	1112	1114	at
I-outcome-Measure	1115	1117	12
I-outcome-Measure	1118	1124	months
I-outcome-Measure	1125	1130	after
I-outcome-Measure	1131	1134	end
I-outcome-Measure	1135	1137	of
I-outcome-Measure	1138	1150	chemotherapy
O	1151	1154	was
O	1155	1158	the
O	1159	1166	primary
O	1167	1174	outcome
O	1174	1175	.

B-outcome-Measure	1176	1192	Postchemotherapy
I-outcome-Measure	1193	1201	hormonal
O	1202	1205	and
B-outcome-Measure	1206	1216	ultrasound
I-outcome-Measure	1217	1224	changes
O	1225	1229	were
O	1230	1239	secondary
O	1240	1248	outcomes
O	1248	1249	.

O	1250	1256	Twelve
O	1257	1263	months
O	1264	1269	after
O	1270	1281	termination
O	1282	1284	of
O	1285	1297	chemotherapy
O	1297	1298	,
O	1299	1304	there
O	1305	1309	were
O	1310	1312	no
O	1313	1324	differences
O	1325	1327	in
B-outcome	1328	1340	menstruation
I-outcome	1341	1351	resumption
I-outcome	1352	1357	rates
O	1358	1365	between
O	1366	1370	GnRH
O	1370	1371	-
O	1371	1378	treated
O	1379	1387	patients
O	1388	1391	and
O	1392	1399	control
O	1400	1405	group
O	1406	1417	individuals
O	1418	1420	in
O	1421	1427	either
O	1428	1433	early
O	1434	1435	(
B-iv-bin-percent	1435	1437	80
I-iv-bin-percent	1437	1438	%
O	1439	1441	in
O	1442	1446	arms
O	1447	1448	I
O	1449	1452	and
O	1453	1455	II
O	1455	1456	,
O	1457	1461	risk
O	1462	1467	ratio
O	1468	1469	1
O	1469	1470	,
O	1471	1473	95
O	1473	1474	%
O	1475	1485	confidence
O	1486	1494	interval
O	1495	1496	0
O	1496	1497	.
O	1497	1498	7
O	1498	1499	-
O	1499	1500	.
O	1500	1502	32
O	1502	1503	;
O	1504	1505	P
O	1505	1506	=
O	1506	1507	1
O	1507	1508	.
O	1508	1510	00
O	1510	1511	)
O	1512	1514	or
O	1515	1522	delayed
O	1523	1535	chemotherapy
O	1536	1542	groups
O	1543	1544	(
B-cv-bin-percent	1544	1546	80
I-cv-bin-percent	1546	1547	%
O	1548	1551	and
B-iv-bin-percent	1552	1554	84
I-iv-bin-percent	1554	1555	%
O	1556	1558	in
O	1559	1563	arms
O	1564	1567	III
O	1568	1571	and
O	1572	1574	IV
O	1574	1575	,
O	1576	1580	risk
O	1581	1586	ratio
O	1587	1588	0
O	1588	1589	.
O	1589	1591	95
O	1591	1592	,
O	1593	1595	95
O	1595	1596	%
O	1597	1607	confidence
O	1608	1616	interval
O	1617	1618	0
O	1618	1619	.
O	1619	1621	73
O	1621	1622	-
O	1622	1623	1
O	1623	1624	.
O	1624	1627	235
O	1627	1628	;
O	1629	1630	P
O	1630	1631	=
O	1631	1632	.
O	1632	1634	71
O	1634	1635	)
O	1635	1636	.

O	1637	1642	There
O	1643	1647	were
O	1648	1650	no
O	1651	1662	differences
O	1663	1665	in
B-outcome	1666	1674	hormonal
I-outcome	1675	1678	and
I-outcome	1679	1689	ultrasound
I-outcome	1690	1697	markers
O	1698	1705	between
O	1706	1710	GnRH
O	1711	1719	analogue
O	1720	1725	users
O	1726	1729	and
O	1730	1737	control
O	1738	1743	group
O	1744	1755	individuals
O	1755	1756	.

O	1757	1760	The
O	1761	1764	use
O	1765	1767	of
O	1768	1772	GnRH
O	1773	1781	analogue
O	1782	1793	cotreatment
O	1794	1797	did
O	1798	1801	not
O	1802	1809	predict
O	1810	1823	independently
O	1824	1827	the
O	1828	1832	odds
O	1833	1835	of
O	1836	1848	menstruating
O	1849	1851	at
O	1852	1854	12
O	1855	1861	months
O	1861	1862	.

O	1863	1867	GnRH
O	1868	1876	analogue
O	1877	1888	cotreatment
O	1889	1893	does
O	1894	1897	not
O	1898	1903	offer
O	1904	1905	a
O	1906	1917	significant
O	1918	1928	protective
O	1929	1935	effect
O	1936	1938	on
O	1939	1946	ovarian
O	1947	1955	function
O	1956	1958	in
O	1959	1967	patients
O	1968	1975	treated
O	1976	1978	by
O	1979	1995	cyclophosphamide
O	1995	1996	-
O	1996	2001	based
O	2002	2014	chemotherapy
O	2014	2015	.

O	2016	2026	Australian
O	2027	2030	New
O	2031	2038	Zealand
O	2039	2047	Clinical
O	2048	2054	Trials
O	2055	2063	Registry
O	2063	2064	.
O	2065	2068	www
O	2068	2069	.
O	2069	2075	anzctr
O	2075	2076	.
O	2076	2079	org
O	2079	2080	.
O	2080	2082	au
O	2082	2083	,
O	2084	2103	ACTRN12609001059257
O	2103	2104	.

O	2105	2106	I
O	2106	2107	.
